The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
Site Search
Showing 211 - 220 of 220 results
News
|
Aug. 31, 2012
|
2 min read
News
|
May 25, 2012
|
2 min read
News
|
Oct. 25, 2012
|
2 min read
News
|
April 19, 2012
|
3 min read
News
|
Dec. 21, 2012
|
3 min read
News
|
Aug. 31, 2012
|
1 min read
News
|
Feb. 6, 2017
|
1 min read
On Aug. 27, leaders from the Cystic Fibrosis Foundation, along with several people from the CF community, participated in a virtual public meeting hosted by the Institute for Clinical and Economic Review to provide insights and expertise on the value of CFTR modulators.
News
|
Sept. 27, 2020
|
3 min read
A transformative leader for more than two decades, Marshall will transition to advisory role
News
|
March 6, 2024
|
3 min read
Hearing from diverse voices is critical as we continue our journey to listen, learn, and take action against racism and discrimination.
News
|
Nov. 18, 2020
|
3 min read